BioPharma Resources

Investigational drug · Phase 3

Tiespectus

Also called: EYE201, MK-8748

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

5

Any phase or sponsor naming "Tiespectus"

First trial start

2024

Nov 12, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tiespectus", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Macular Degeneration
  • Age-Related Macular Degeneration
  • Choroidal Neovascularization
  • Wet Macular Degeneration
  • Diabetic Retinopathy
  • Macular Edema
  • Diabetic Macular Edema (DME)
  • Neovascular Age-related Macular Degeneration (NVAMD)
  • BRVO - Branch Retinal Vein Occlusion

Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Tiespectus" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Macular Degeneration

  • JNJ-81201887AAVCAGsCD59Phase 32 trials

    Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration

  • AVD-104Phase 21 trial

    Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration

  • SYL1801Phase 21 trial

    Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.